Acumen’s Alzheimer’s drug passes initial safety test
By Julie Steenhuysen CHICAGO (Reuters) – An experimental Alzheimer’s disease drug developed by Acumen Pharmaceuticals targeting a novel form of the toxic protein beta amyloid in the brain passed an early safety test and will advance to a larger trial, the company said on Sunday. The drug, ACI193, was well tolerated in the first trial…